The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: Earnings Drive Mixed UK Stocks, As BOE Stands Pat

Wed, 22nd Oct 2014 09:49

LONDON (Alliance News) - UK stocks are putting in a mixed performance Wednesday, with company earnings driving the main stock movers.

Meanwhile, the pound has fallen heavily against other major major currencies after the minutes of the Bank of England's latest monetary policy meeting showed increasing concern amongst rate setters over a slowdown in global growth, particularly in the eurozone.

By mid-morning Wednesday the FTSE 100 is down 0.2% at 6,361.48, while the FTSE 250 is up 0.5% at 15,098.77, and the AIM All-Share is up 0.3% at 706.98.

Major European markets are also mixed, with the French CAC 40 down 0.1%, and the German DAX 30 down 0.2%.

The minutes of the October Monetary Policy Committee meeting earlier this month showed that rate setters for the Bank of England voted 7-2 to keep the UK's base interest rate on hold at 0.5%, in line with expectations. The two members voting for a rate hike were Martin Weale and Ian McCafferty. The MPC members voted unanimously to maintain the BoE's stock of purchased assets at GBP375 billion, also in line with expectations.

There had been very little expectation of a shift in the voting pattern from the September minutes. There has been little reason to turn more hawkish over the last month, given the slowdown in eurozone growth and a pick up in market volatility, but it also seemed unlikely that Weale and McCafferty would retract their votes for a rate hike just one month after sticking their necks out on the issue.

While the vote was therefore in line with expectations, the minutes have been taken as doveish due to the increased concern evident among that rate setters about the global growth slowdown, particularly in the eurozone, and the damaging effect it could have on the UK economy.

"Once again, the news on global activity and inflation had, on balance, been modestly to the downside, particularly in the euro area," the minutes read. "There were increasing indications that the slight slowing in the pace of (UK) expansion towards the end of the year that the Committee had been expecting for some time would indeed occur."

The effect of the cautious tone was felt in the pound, which has fallen to a four-day low against the dollar of USD1.6010. Against the euro the pound also slipped, despite the euro remaining under pressure amid reports of the European Central Bank discussing bond buying in an effort to boost the region's slowing growth. Currently the pound buys EUR1.2630.

The euro, the European banking system, and the wider economy are in focus ahead of the weekend when the results of stress tests on banks within the eurozone are due. According to a report from the Spanish news agency Efe, at least 11 banks of the 130 being tested are set to fail the tests. An ECB spokesperson has since said that the Efe report is entirely speculative at this stage.

On the London equities market, British American Tobacco is the worst FTSE 100 performer, down 4.2% after saying that its profitability has been hit by the relative strength of the pound. The cigarette maker said its nine-month revenue was up 2.4% at constant exchange rates but down 9.6% at actual rates. Imperial Tobacco has followed a little lower, down 0.9%.

The motor insurers Direct Line and Admiral are the best blue chip performers, up 2.7% and 2.5%, respectively, following a report from the AA that said insurance premiums have risen by 1.2% over the three months to September 30, which is reportedly the first rise in premiums in more than two years.

FTSE 250-listed Playtech is the best performer in the index, up 5.8% after reporting faster that expected revenue growth, particularly in Asia, where revenue for the gaming group was up 85%, after being up 72% in the first half.

International Personal Finance is up 4.4% after reporting a 5% rise in pretax profit in the third quarter to GBP34.0 million, up from GBP32.5 million a year earlier. Revenue rose to GBP245.5 million from GBP264.4 million, helped by a 4.8% increase in customer numbers to 2.6 million.

SuperGroup is the worst performing FTSE 250 listing. The fashion retailer said it has appointed Non-Executive Director Euan Sutherland as its new chief executive, with founder Julian Dunkerton moving to the newly created role of founder and product and brand director, a move the company said would assist an accelerated expansion overseas. Analyst also have trimmed full-year estimates for the company due to the warm UK weather that has hit the clothing retail sector in general.

Still to come Wednesday, GlaxoSmithKline is due to report third quarter numbers at midday, with the market expectant to hear of any financial detail around the development of a vaccine against Ebola, after the company said it is working at an "unprecedented rate" on the issue.

US consumer price inflation at 1330 BST will be of keen interest given the heightened concerns over the strength of the economy as monetary stimulus is withdrawn. The expectation is for a slight fall in CPI to 1.6% year-on-year in September, from 1.7% in August. The US, like the UK, targets 2.0% inflation, and anything greater than the expected 0.1-percentage-point fall will likely cause some concern, analysts say.

US third quarter earnings season is in full flow, with a raft of numbers due Wednesday, including from AT&T Inc and Boeing Company.

Futures currently indicate that Wall Street will follow European markets to a mixed open, with the DJIA and the S&P 500 pointing down 0.1%, but the Nasdaq Composite up 0.1%.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.